Mobile
Search
Advanced search
Multi-criteria search
Who are we ?
Log in
Sign up
Français
English
Kusajili – Clinical trials directory
Send this study to a contact
1
Your personal information
Your name
Your e-mail
Send me a copy
2
Your recipient's information
The name of your contact
Your contact email
3
Your message
Votre message
A phase III, double-blind, randomized, placebo-controlled, multi-center study evaluating the efficacy and safety of dalcetrapib on lipids, lipoproteins, apolipoproteins and markers of CV risk in patients hospitalized for an acute coronary syndrome (ACS) when treatment is initiated within 1 week after an ACS (dal-ACUTE) https://www.kusajili.fr:443/Trial/3Dzuf8EuqkKLVx48D746kA%24a-phase-iii-double-blind-randomized-placebo-controlled-multi-center-study-evaluating-the-efficacy-and-safety-of-dalcetrapib-on-
I have read and accept the terms of use of the site and the Privacy Policy
Send your message